The Diagnostic Accuracy of HE4 in Lung Cancer: A Meta-Analysis

Abstract EN

The diagnostic value of serum HE4 in patients with lung cancer remains controversial.

Thus, we performed a systematic review and meta-analysis to assess the diagnostic accuracy of serum HE4 for lung cancer.

We conducted a comprehensive literature search in PubMed, EMBASE, Chinese National Knowledge Infrastructure (CNKI), and WANFANG databases between Jan.

1966 and Nov.

2014.

The diagnostic sensitivity (SEN), specificity (SPE), positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and summary receiver operating characteristic curve (SROC) were pooled by Meta-DiSc 1.4 software.

A total of seven articles including 715 cases and 549 controls were included for analysis.

The summary estimates for serum HE4 in the diagnosis of lung cancer in these studies were pooled SEN 0.72 (95% CI: 0.68–0.75), SPE 0.85 (95% CI: 0.81–0.88), PLR 4.68 (95% CI: 3.23–6.78), NLR 0.31 (95% CI: 0.24–0.39), and DOR 17.14 (95% CI: 9.72–30.20), and the area under the curve (AUC) was 0.8557.

This meta-analysis indicated that serum HE4 is a potential tool in the diagnosis of lung cancer.

In addition, considering the high heterogeneity and potential publication bias, further studies with rigorous design and large sample size are needed in the future.